Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
Medina Lara A, Kigozi J, Amurwon J, Muchabaiwa L, Nyanzi Wakaholi B, Mujica Mota RE, Walker AS, Kasirye R, Ssali F, Reid A, Grosskurth H, Babiker AG, Kityo C, Katabira E, Munderi P, Mugyenyi P, Hakim J, Darbyshire J, Gibb DM, Gilks CF; DART Trial Team. Medina Lara A, et al. Among authors: mugyenyi p. PLoS One. 2012;7(4):e33672. doi: 10.1371/journal.pone.0033672. Epub 2012 Apr 24. PLoS One. 2012. PMID: 22545079 Free PMC article. Clinical Trial.
A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria.
Gilks CF, Walker AS, Munderi P, Kityo C, Reid A, Katabira E, Goodall RL, Grosskurth H, Mugyenyi P, Hakim J, Gibb DM; DART Virology Group and Trial Team. Gilks CF, et al. Among authors: mugyenyi p. PLoS One. 2013;8(2):e57580. doi: 10.1371/journal.pone.0057580. Epub 2013 Feb 21. PLoS One. 2013. PMID: 23437399 Free PMC article. Clinical Trial.
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Kityo C, Gibb DM, Gilks CF, Goodall RL, Mambule I, Kaleebu P, Pillay D, Kasirye R, Mugyenyi P, Walker AS, Dunn DT; DART Trial Team. Kityo C, et al. Among authors: mugyenyi p. PLoS One. 2014 Mar 13;9(3):e90772. doi: 10.1371/journal.pone.0090772. eCollection 2014. PLoS One. 2014. PMID: 24625508 Free PMC article. Clinical Trial.
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
DART Trial Team; Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, Reid A, Grosskurth H, Darbyshire JH, Ssali F, Bray D, Katabira E, Babiker AG, Gilks CF, Grosskurth H, Munderi P, Kabuye G, Nsibambi D, Kasirye R, Zalwango E, Nakazibwe M, Kikaire B, Nassuna G, Massa R, Fadhiru K, Namyalo M, Zalwango A, Generous L, Khauka P, Rutikarayo N, Nakahima W, Mugisha A, Todd J, Levin J, Muyingo S, Ruberantwari A, Kaleebu P, Yirrell D, Ndembi N, Lyagoba F, Hughes P, Aber M, Lara AM, Foster S, Amurwon J, Wakholi BN, Whitworth J, Wangati K, Amuron B, Kajungu D, Nakiyingi J, Omony W, Fadhiru K, Nsibambi D, Khauka P, Mugyenyi P, Kityo C, Ssali F, Tumukunde D, Otim T, Kabanda J, Musana H, Akao J, Kyomugisha H, Byamukama A, Sabiiti J, Komugyena J, Wavamunno P, Mukiibi S, Drasiku A, Byaruhanga R, Labeja O, Katundu P, Tugume S, Awio P, Namazzi A, Bakeinyaga GT, Katabira H, Abaine D, Tukamushaba J, Anywar W, Ojiambo W, Angweng E, Murungi S, Haguma W, Atwiine S, Kigozi J, Namale L, Mukose A, Mulindwa G, Atwiine D, Muhwezi A, Nimwesiga E, Barungi G, Takubwa J, Murungi S, Mwebesa D, Kagina G, Mulindwa M, Ahimbisibwe F, Mwesigwa P, Akuma S, Zawedde C, Nyiraguhirwa D, Tumusiime C, … See abstract for full author list ➔ DART Trial Team, et al. Among authors: mugyenyi p. Lancet. 2010 Jan 9;375(9709):123-31. doi: 10.1016/S0140-6736(09)62067-5. Epub 2009 Dec 8. Lancet. 2010. PMID: 20004464 Free PMC article. Clinical Trial.
A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda.
Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, Mbamanya F, Ssali F, Dewar R, Daucher M, Davey RT Jr, Mugyenyi P, Fauci AS, Quinn TC, Dybul MR. Reynolds SJ, et al. Among authors: mugyenyi p. PLoS One. 2010 Apr 22;5(4):e10307. doi: 10.1371/journal.pone.0010307. PLoS One. 2010. PMID: 20442758 Free PMC article. Clinical Trial.
Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
Walker AS, Prendergast AJ, Mugyenyi P, Munderi P, Hakim J, Kekitiinwa A, Katabira E, Gilks CF, Kityo C, Nahirya-Ntege P, Nathoo K, Gibb DM; DART and ARROW trial teams. Walker AS, et al. Among authors: mugyenyi p. Clin Infect Dis. 2012 Dec;55(12):1707-18. doi: 10.1093/cid/cis797. Epub 2012 Sep 12. Clin Infect Dis. 2012. PMID: 22972859 Free PMC article.
Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART.
Kiwuwa-Muyingo S, Oja H, Walker A, Ilmonen P, Levin J, Mambule, Reid A, Mugyenyi P, Todd J; DART Trial team. Kiwuwa-Muyingo S, et al. Among authors: mugyenyi p. BMC Infect Dis. 2013 Aug 27;13:395. doi: 10.1186/1471-2334-13-395. BMC Infect Dis. 2013. PMID: 24060199 Free PMC article. Clinical Trial.
Sustainable and cost-effective monitoring of patients on ART.
Gibb DM, Mugyenyi P. Gibb DM, et al. Among authors: mugyenyi p. Lancet Glob Health. 2014 Jan;2(1):e4-5. doi: 10.1016/S2214-109X(13)70081-0. Epub 2013 Dec 10. Lancet Glob Health. 2014. PMID: 25104634 Free article. No abstract available.
182 results